The Peter Doherty Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Melbourne Australia (2014)

Organization Overview

First Clinical Trial
2016
NCT02765126
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

The Peter Doherty Institute for Infection and Immunity